aXichem AB (AXIC-A) - Cash Flow Conversion Efficiency
Based on the latest financial reports, aXichem AB (AXIC-A) has a cash flow conversion efficiency ratio of -0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-1.98 Million ≈ $-213.40K USD) by net assets (Skr58.07 Million ≈ $6.25 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See defensive interval ratio of aXichem AB to measure how many days the company can operate on defensive assets alone.
aXichem AB - Cash Flow Conversion Efficiency Trend (2008–2024)
This chart illustrates how aXichem AB's cash flow conversion efficiency has evolved over time, based on yearly financial data.
aXichem AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of aXichem AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Target Healthcare REIT Ltd
LSE:THRL
|
0.033x |
|
Golden Pharos Bhd
KLSE:5649
|
-0.057x |
|
ALERIO GOLD CORP.
F:3FR0
|
N/A |
|
California Nanotechnologies Corp
V:CNO
|
-0.078x |
|
Bulletin Resources Ltd
AU:BNR
|
-0.046x |
|
Eros International Media Limited
NSE:EROSMEDIA
|
-0.061x |
|
Workspace Group PLC
LSE:WKP
|
0.018x |
|
EA Holdings Bhd
KLSE:0154
|
-0.070x |
Annual Cash Flow Conversion Efficiency for aXichem AB (2008–2024)
The table below shows the annual cash flow conversion efficiency of aXichem AB from 2008 to 2024. For the full company profile with market capitalisation and key ratios, see how much is aXichem AB worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr70.16 Million ≈ $7.55 Million |
Skr-11.50 Million ≈ $-1.24 Million |
-0.164x | +49.25% |
| 2023-12-31 | Skr48.53 Million ≈ $5.22 Million |
Skr-15.68 Million ≈ $-1.69 Million |
-0.323x | +31.78% |
| 2022-12-31 | Skr40.33 Million ≈ $4.34 Million |
Skr-19.10 Million ≈ $-2.06 Million |
-0.474x | -70.97% |
| 2021-12-31 | Skr56.30 Million ≈ $6.06 Million |
Skr-15.60 Million ≈ $-1.68 Million |
-0.277x | -27.08% |
| 2020-12-31 | Skr53.65 Million ≈ $5.77 Million |
Skr-11.69 Million ≈ $-1.26 Million |
-0.218x | -19.06% |
| 2019-12-31 | Skr67.15 Million ≈ $7.23 Million |
Skr-12.29 Million ≈ $-1.32 Million |
-0.183x | +28.60% |
| 2018-12-31 | Skr29.10 Million ≈ $3.13 Million |
Skr-7.46 Million ≈ $-802.92K |
-0.256x | -12.93% |
| 2017-12-31 | Skr33.86 Million ≈ $3.64 Million |
Skr-7.69 Million ≈ $-827.35K |
-0.227x | -69.82% |
| 2016-12-31 | Skr41.33 Million ≈ $4.45 Million |
Skr-5.53 Million ≈ $-594.69K |
-0.134x | +55.97% |
| 2015-12-31 | Skr26.27 Million ≈ $2.83 Million |
Skr-7.98 Million ≈ $-858.45K |
-0.304x | +36.22% |
| 2014-12-31 | Skr18.93 Million ≈ $2.04 Million |
Skr-9.01 Million ≈ $-970.05K |
-0.476x | -176.29% |
| 2013-12-31 | Skr24.92 Million ≈ $2.68 Million |
Skr-4.29 Million ≈ $-462.10K |
-0.172x | +71.74% |
| 2012-12-31 | Skr8.01 Million ≈ $862.30K |
Skr-4.89 Million ≈ $-525.79K |
-0.610x | -1199.16% |
| 2011-12-31 | Skr9.13 Million ≈ $982.51K |
Skr-428.50K ≈ $-46.11K |
-0.047x | +86.41% |
| 2010-12-31 | Skr3.28 Million ≈ $352.46K |
Skr-1.13 Million ≈ $-121.77K |
-0.345x | +34.91% |
| 2009-12-31 | Skr5.65 Million ≈ $607.93K |
Skr-3.00 Million ≈ $-322.68K |
-0.531x | -152.73% |
| 2008-12-31 | Skr7.37 Million ≈ $792.98K |
Skr7.42 Million ≈ $798.20K |
1.007x | -- |
About aXichem AB
aXichem AB, a biotechnology company, engages in the development of natural analogue ingredients in Sweden. It offers aXivite, a natural analogue capsaicin solution for a range of dietary health applications; aXiphen-bio, a bio-repellent for antifouling protection for vessels and marine installations, pest control in agriculture and forestry, and pest control for cable installations in buildings a… Read more